WO1998055113A1 - Semisolid pharmaceutical formulation containing dexketoprofen trometamol - Google Patents

Semisolid pharmaceutical formulation containing dexketoprofen trometamol Download PDF

Info

Publication number
WO1998055113A1
WO1998055113A1 PCT/EP1998/003333 EP9803333W WO9855113A1 WO 1998055113 A1 WO1998055113 A1 WO 1998055113A1 EP 9803333 W EP9803333 W EP 9803333W WO 9855113 A1 WO9855113 A1 WO 9855113A1
Authority
WO
WIPO (PCT)
Prior art keywords
tromethamine
agent
pharmaceutical formulation
gel
dexketoprofen
Prior art date
Application number
PCT/EP1998/003333
Other languages
French (fr)
Inventor
David Mauleon Casellas
Luisa Garcia Perez
Albert Palomer Benet
Original Assignee
Laboratorios Menarini S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to UA99116289A priority Critical patent/UA57075C2/en
Priority to PL337156A priority patent/PL190779B1/en
Priority to SK1649-99A priority patent/SK284317B6/en
Priority to JP50151599A priority patent/JP2002502407A/en
Priority to EP98937444A priority patent/EP0996437B1/en
Priority to DE69800804T priority patent/DE69800804T2/en
Priority to BRPI9810072-6A priority patent/BR9810072B1/en
Priority to KR1019997011315A priority patent/KR100543558B1/en
Priority to EA199900998A priority patent/EA002026B1/en
Priority to AT98937444T priority patent/ATE201137T1/en
Application filed by Laboratorios Menarini S.A. filed Critical Laboratorios Menarini S.A.
Priority to CA002293589A priority patent/CA2293589C/en
Priority to AU86244/98A priority patent/AU728442B2/en
Priority to EEP199900556A priority patent/EE03905B1/en
Priority to NZ501487A priority patent/NZ501487A/en
Priority to HU0002734A priority patent/HU226686B1/en
Priority to DK98937444T priority patent/DK0996437T3/en
Publication of WO1998055113A1 publication Critical patent/WO1998055113A1/en
Priority to BG103926A priority patent/BG64299B1/en
Priority to HK00106945A priority patent/HK1027753A1/en
Priority to GR20010401170T priority patent/GR3036319T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to a process for the preparation of a semisolid pharmaceutical formulation (gel or cream) containing dexketoprofen tro etamol and different amines as neutralizing agents, for the topical treatment of inflammatory processes in humans.
  • the pharmaceutical formulations obtained by said process are also object of the present invention and show advantages deriving from their high storage stability without noticeable changes in the appearance of the product in time, a well as from their lower allergenic and photoallergenic activities.
  • NSAID used in therapy for example arylpropionic or arylacetic acids derivatives
  • Carboxyvinyl polymers can be used as gelifying agents in the preparation of gels with this type of NSAID, these polymers need the mandatory presence of a neutralizing base to increase their viscosity and to attain their correct gelification.
  • the base In order to obtain a good gelification with this type of compounds, the base has to neutralize both the gelifying agent and the active principle.
  • the most widely used bases for this purpose are amines, such as triethanolamine and diethanolamine .
  • tromethamine DCI trometamol, 2-amino-2-(hydroxyethyl )-l, 3-propanediol
  • tromethamine has also been used as neutralizing agent in the preparation of gels for therapeutic use, due to its suitable physical- chemical characteristics as well as to its low toxicity (Bremecker K.D. Pharm. Ind. 51 (2) 199-202 (1989)).
  • Tromethamine has remarkable advantages both from the physical-chemical and from the toxicologic point of view, compared with the commonly used amines, such as triethanolamine and diethanolamine.
  • triethanolamine and diethanolamine proved to be potentially harmful, in particular carcinogenic, compounds both in in vi tro cellular models (Santa aria A. et al. ⁇ cotoxicol. Environ. Saf.
  • tromethamine itself is used as a medicament in respiratory and metabolic acidosis syndromes (USP XXIII and European Pharmacopoeia 3rd Ed.).
  • tromethamine has recently been used also as neutralizing agent in the preparation of gels for the therapeutic use.
  • the physical characteristics of the resulting pharmaceutical formulations are similar to those obtained with triethanolamine, as far as pH, viscosity, organoleptic characteristics and storage stability are concerned (Kim H. et al. JP 07309938, 1995 and Tamburick S. et al. Pharm. Res. 13 (2) 279-83 (1996)).
  • tromethamine as neutralizing agent allows, due to its lower basicity, to add the a ine in larger amounts than the stoic iometric and, as a consequence, the maximum viscosity area does not take place after the stoichiometric addition of the amine, as it happens when using triethanolamine or diethanolamine, but after the addition of larger amounts of the amine, the buffering power of the resulting formulation being much higher
  • Tromethamine has been used in pharmaceutical semisolid formulations (gels and liposomes) for the treatment of acne and psoriasis ( Charu P.M. WO 9533489, 1995 and Hager J.-C. DE 4322158, 1995), in oxytocic gels containing prostaglandins ⁇ , A and F2a (Kravciv M. et al.
  • ketorolac tromethamine salt for the administration of this compound in the form of dentifrice gel (Cavanaugh P.F. et al. WO-9628144 Al ,
  • the present invention aims therefore at obtaining gels of the analgesic and antiinflammatory medicament dexketoprofen trometamol having a complete storage stability without noticeable changes in the appearance of the product in time.
  • a polyacrylic gel of an arylpropionic acid can be prepared starting from the active principle as the free acid, dissolving it in a suitable solvent such as ethanol and adding it with a dispersion formed by carbomer and water; finally, neutralizing it with a physiologically compatible amine, such as triethanolamine, diethanolamine or tromethamine, to obtain the desired gel.
  • a physiologically compatible amine such as triethanolamine, diethanolamine or tromethamine
  • the dexketoprofen trometamol gel prepared with tromethamine turned out to be remarkably less photoallergenic than conventional gels.
  • dexketoprofen trometamol as therapeutical agent together with diethanolamine or triethanolamine may be considered when a reduction in the amine content in the gel is desired.
  • the process for the preparation of a gel containing dexketoprofen trometamol at a concentration ranging between 1.5 and 4.5% typically comprises the formation first of a dispersion containing 0.5 to 5% of carbomer, 10-40% of ethanol and 60-90% of demineralized water, optionally in the presence of a suitable essence oil (0.05-0.5%).
  • This dispersion is then added with a solution containing dexketoprofen trometamol (from 1.5 to 4.5% on the total amount of gel) and a suitable amine (from 0.5 to 3% on the total amount of gel), such as tromethamine, triethanolamine or diethanolamine, in demineralized water (4-10% on the basis of the total amount of gel).
  • a suitable amine from 0.5 to 3% on the total amount of gel
  • pH is checked to range between 5 and 7, preferably between 6 and 6.5.
  • the gel is de-aerated under mild vacuum.
  • dexketoprofen trometamol can also be prepared in si tu.
  • the process consists in the preparation of a 1-3% dexketoprofen solution on the basis of the total amount of gel in ethanol (25-40%) containing a suitable essence oil (0.05-0.5%), which solution is then added with a dispersion of 0.5-5% of carbomer in water. After a suitable time from 15 to 30 min. for the correct homogenization of the formed dispersion, tromethamine is added in an equimolar amount to dexketoprofen (between
  • a physiologically compatible amine such as triethanolamine, diethanolamine or tromethamine
  • the gels of the invention have a long-term storage stability under conventional conditions (15-35°C) for long periods of time and exhibit excellent antiinflam a- tory and analgesic effects without involving noticeable toxic effects when directly applied to the skin.
  • Example 1 Preparation of a gel starting from tromethamine ( + )-(S)-2-( 3-benzoylphenyl )propionate using tromethamine as neutralizing agent.
  • a 200 L reactor equipped with a stirrer is loaded with 40.8 L of ethanol, 0.1 kg of a suitable essence oil, 57.5 L of demineralized water and 1.5 kg of carbomer.
  • the mixture is stirred to a homogeneous dispersion (15 min).
  • the resulting dispersion is added with a solution of 1.4 kg of tromethamine, 1.85 kg of tromethamine (+)-(S)-2-(3-benzoylphenyl)propionate and 5.65 L of water, stirring to obtain a correct incorporation (15 min). After this time, stirring is stopped and pH is checked to range from 6 to 6.5. Finally, the resulting gel is de-aerated under mild vacuu .
  • Example 2 Preparation of a gel starting from tromethamine ( + )-(S )-2-( 3-benzoylphenyl )propionate using diethanolamine as neutralizing agent.
  • a 200 L reactor equipped with a stirrer is loaded with 40.8 L of ethanol, 0.1 kg of a suitable essence oil, 57.5 L of demineralized water and 1.5 kg of carbomer.
  • the mixture is stirred to a homogeneous dispersion (15 min).
  • the resulting dispersion is added with a solution of 1.04 kg of diethanolamine, 1.85 kg of tromethamine (+ )-(S)-2-( 3-benzoylphenyl )propionate and 6.01 L of water, stirring to obtain a correct incorporation (15 min). After this time, stirring is stopped and pH is checked to range from 6 to 6.5. Finally, the resulting gel is de-aerated under mild vacuum.
  • Example 3 Preparation of a gel starting from tromethamine ( + )-( S )-2-( 3-benzoylphenyl )propionate using triethanolamine as neutralizing agent.
  • a 200 L reactor equipped with a stirrer is loaded with 40.8 L of ethanol, 0.1 kg of a suitable essence oil, 57.5 L of demineralized water and 1.5 kg of carbomer.
  • the mixture is stirred to a homogeneous dispersion (15 min).
  • the resulting dispersion is added with a solution of 1.58 kg of triethanolamine, 1.85 kg of tromethamine (+)-(S)-2-(3-benzoylphenyl)propionate and 5.47 L of water, stirring to obtain a correct incorporation (15 min). After this time, stirring is stopped and pH is checked to range from 6 to 6.5. Finally, the resulting gel is de-aerated under mild vacuum.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a process for the preparation of a semisolid pharmaceutical formulation (gel or cream) containing dexketoprofen trometamol and different amines as neutralizing agents, for the topical treatment of inflammatory processes in humans. The pharmaceutical formulations object of the present invention show advantages deriving from their high storage stability without noticeable changes in the appearance of the product in time, as well as from their lower allergenic and photoallergenic activities.

Description

SEMISOLID PHARMACEUTICAL FORMULATION CONTAINING DEXKETOPROFEN TROMETAMOL
FIELD OF THE INVENTION
The present invention relates to a process for the preparation of a semisolid pharmaceutical formulation (gel or cream) containing dexketoprofen tro etamol and different amines as neutralizing agents, for the topical treatment of inflammatory processes in humans. The pharmaceutical formulations obtained by said process are also object of the present invention and show advantages deriving from their high storage stability without noticeable changes in the appearance of the product in time, a well as from their lower allergenic and photoallergenic activities. DESCRIPTION OF THE PRIOR ART
The use of semisolid formulations (gels or creams) of non steroidal antiinflammatory agents (NSAIDS) is common in the topical treatment of inflammatory syndromes.
Most NSAID used in therapy, for example arylpropionic or arylacetic acids derivatives, have an acid function in their structure. Carboxyvinyl polymers (carbo er or carbopol(R)) can be used as gelifying agents in the preparation of gels with this type of NSAID, these polymers need the mandatory presence of a neutralizing base to increase their viscosity and to attain their correct gelification. In order to obtain a good gelification with this type of compounds, the base has to neutralize both the gelifying agent and the active principle. The most widely used bases for this purpose are amines, such as triethanolamine and diethanolamine . Recently, tromethamine [DCI trometamol, 2-amino-2-(hydroxyethyl )-l, 3-propanediol] has also been used as neutralizing agent in the preparation of gels for therapeutic use, due to its suitable physical- chemical characteristics as well as to its low toxicity (Bremecker K.D. Pharm. Ind. 51 (2) 199-202 (1989)).
Tromethamine has remarkable advantages both from the physical-chemical and from the toxicologic point of view, compared with the commonly used amines, such as triethanolamine and diethanolamine. As far as its physical-chemical characteristics are concerned, tromethamine is a weakly basic polar amine (p ^ = 7.8) which forms buffer solutions of about the plasma pH, therefore it is also used as isotonic solution (Martindale 31st Ed. ) and to control the body and blood pH during transfusions. From the toxicologic point of view, triethanolamine and diethanolamine proved to be potentially harmful, in particular carcinogenic, compounds both in in vi tro cellular models (Santa aria A. et al. Ξcotoxicol. Environ. Saf. 34 (1) 56-58 (1996)) and in vivo in rodents (Konishi Y. et al. Fundament . APPI. Toxicol. 18 (1) 25-29 (1992); Melnick R. L. et al. J. APPI. Toxicol. 14 (1) 1-9 (1994) and ibid. 14 (1) 1-9 (1994)), by oral as well as by topical administration. On the other hand, when included in creams and gels, triethanolamine caused irritating reactions resulting from its combination with other components of the formulation, e.g. stearates. These compounds showed a powerfully irritating action in humans (Batten T. L. et al. Contact Dermatitis 30, 159-161 (1994)). In its turn, tromethamine reduces or removes any risk of formation of carcinogenic nitrosoa ines (Bremecker K.D. Pharm. Ind.
51 (2) 199-202 (1989)), in that, being it a primary amine , it forms unstable nitrosoamines, which decompose in the presence of the nitrosating agent. Moreover, tromethamine itself is used as a medicament in respiratory and metabolic acidosis syndromes (USP XXIII and European Pharmacopoeia 3rd Ed.).
In literature, the preparation of pharmaceutical formulations containing tromethamine for the oral administration of non steroidal antiinflam atory compounds has been described. In these formulations, the therapeutical agent, for example diflunisal, is mixed with tromethamine and the required adjuvants (Phillips A. EP 293529, 1988), or the salt of the therapeutical agent is used, e.g. dexketoprofen trometamol (Carganico G. et al. IS 9202260, 1992), which improves the oral absorption rate of the medicament as well as the onset of its analgesic action.
As mentioned above, tromethamine has recently been used also as neutralizing agent in the preparation of gels for the therapeutic use. The physical characteristics of the resulting pharmaceutical formulations are similar to those obtained with triethanolamine, as far as pH, viscosity, organoleptic characteristics and storage stability are concerned (Kim H. et al. JP 07309938, 1995 and Tamburick S. et al. Pharm. Res. 13 (2) 279-83 (1996)). Moreover, the use of tromethamine as neutralizing agent allows, due to its lower basicity, to add the a ine in larger amounts than the stoic iometric and, as a consequence, the maximum viscosity area does not take place after the stoichiometric addition of the amine, as it happens when using triethanolamine or diethanolamine, but after the addition of larger amounts of the amine, the buffering power of the resulting formulation being much higher
(Bremecker K.D. Pharm. Ind. 51 (2) 199-202 (1989)). Tromethamine has been used in pharmaceutical semisolid formulations (gels and liposomes) for the treatment of acne and psoriasis ( Charu P.M. WO 9533489, 1995 and Hager J.-C. DE 4322158, 1995), in oxytocic gels containing prostaglandins Ξ, A and F2a (Kravciv M. et al. CS 276067, 1992 and CS 277720, 1993)) and, together with salicylic and nicotinic acids, in ointments for the analgesic topical treatment of muscular pain of rheumatic and arthritic origin or post- athletic training pains (GB 1106580, 1968). Finally, semisolid pharmaceutical formulations have been described containing ketorolac tromethamine salt for the administration of this compound in the form of dentifrice gel (Cavanaugh P.F. et al. WO-9628144 Al ,
1996) or of solution for mouth rinse (Cavanaugh P.F. et al. inflammopharmacoloσv 3(4) 313 (1995) and Kelm G.R. et al. J. Pharm. Sci. 85 (8) 842 (1996)) in the treatment of periodontitis and other buccal diseases.
The present invention aims therefore at obtaining gels of the analgesic and antiinflammatory medicament dexketoprofen trometamol having a complete storage stability without noticeable changes in the appearance of the product in time.
According to the prior art, a polyacrylic gel of an arylpropionic acid can be prepared starting from the active principle as the free acid, dissolving it in a suitable solvent such as ethanol and adding it with a dispersion formed by carbomer and water; finally, neutralizing it with a physiologically compatible amine, such as triethanolamine, diethanolamine or tromethamine, to obtain the desired gel. The dexketoprofen gel (at a concentration ranging between 1 and 3%) prepared according to this method, using triethanolamine or diethanolamine as the amine, tends to become muddy after 1-6 months due to the precipitation of the active principle as such or as a salt with the neutralizing amine. This precipitation is even more evident at temperatures below 20°C, which are often those corresponding to the usual storage conditions.
According to the present invention, particurarly using tromethamine as neutralizing agent, no precipitation occurs, thereby obtaining a gel with a high stability (higher than 2 years) and with favourable rheological and thixotropic characteristics.
Surprisingly, when this type of gels is prepared using dexketoprofen trometa ol as active principle instead of dexketoprofen and the amine in just the necessary amount to neutralize the gelifying agent, no precipitation with any of the used amines is observed. A great variety of amines can be used as neutralizing agents, such as triethanolamine, diethanolamine, tromethamine, particularly preferred and convenient being the use of tromethamine also as neutralizing agent, in view of homogeneity with the amine salifying the active principle and, above all, of the lower toxicity exerted.
The dexketoprofen trometamol gel prepared with tromethamine turned out to be remarkably less photoallergenic than conventional gels.
The use of dexketoprofen trometamol as therapeutical agent together with diethanolamine or triethanolamine may be considered when a reduction in the amine content in the gel is desired.
The process for the preparation of a gel containing dexketoprofen trometamol at a concentration ranging between 1.5 and 4.5% (corresponding to 1-3% of dexketoprofen), typically comprises the formation first of a dispersion containing 0.5 to 5% of carbomer, 10-40% of ethanol and 60-90% of demineralized water, optionally in the presence of a suitable essence oil (0.05-0.5%). This dispersion is then added with a solution containing dexketoprofen trometamol (from 1.5 to 4.5% on the total amount of gel) and a suitable amine (from 0.5 to 3% on the total amount of gel), such as tromethamine, triethanolamine or diethanolamine, in demineralized water (4-10% on the basis of the total amount of gel). After that, once the correct gelification takes place, pH is checked to range between 5 and 7, preferably between 6 and 6.5. Finally, the gel is de-aerated under mild vacuum.
When tromethamine is used as neutralizing agent, dexketoprofen trometamol can also be prepared in si tu. In this case, the process consists in the preparation of a 1-3% dexketoprofen solution on the basis of the total amount of gel in ethanol (25-40%) containing a suitable essence oil (0.05-0.5%), which solution is then added with a dispersion of 0.5-5% of carbomer in water. After a suitable time from 15 to 30 min. for the correct homogenization of the formed dispersion, tromethamine is added in an equimolar amount to dexketoprofen (between
0.5 and 1.5%), and finally carbomer is neutralized with
0.5-3% of a physiologically compatible amine, such as triethanolamine, diethanolamine or tromethamine, to adjust pH to 5 - 7, preferably to 6 - 6.5. Finally, the gel is de-aerated under mild vacuum.
The gels of the invention have a long-term storage stability under conventional conditions (15-35°C) for long periods of time and exhibit excellent antiinflam a- tory and analgesic effects without involving noticeable toxic effects when directly applied to the skin. EXAMPLES
The following examples further illustrate the process of the invention. Example 1 : Preparation of a gel starting from tromethamine ( + )-(S)-2-( 3-benzoylphenyl )propionate using tromethamine as neutralizing agent.
A 200 L reactor equipped with a stirrer is loaded with 40.8 L of ethanol, 0.1 kg of a suitable essence oil, 57.5 L of demineralized water and 1.5 kg of carbomer. The mixture is stirred to a homogeneous dispersion (15 min). The resulting dispersion is added with a solution of 1.4 kg of tromethamine, 1.85 kg of tromethamine (+)-(S)-2-(3-benzoylphenyl)propionate and 5.65 L of water, stirring to obtain a correct incorporation (15 min). After this time, stirring is stopped and pH is checked to range from 6 to 6.5. Finally, the resulting gel is de-aerated under mild vacuu .
Example 2: Preparation of a gel starting from tromethamine ( + )-(S )-2-( 3-benzoylphenyl )propionate using diethanolamine as neutralizing agent.
A 200 L reactor equipped with a stirrer is loaded with 40.8 L of ethanol, 0.1 kg of a suitable essence oil, 57.5 L of demineralized water and 1.5 kg of carbomer. The mixture is stirred to a homogeneous dispersion (15 min). The resulting dispersion is added with a solution of 1.04 kg of diethanolamine, 1.85 kg of tromethamine (+ )-(S)-2-( 3-benzoylphenyl )propionate and 6.01 L of water, stirring to obtain a correct incorporation (15 min). After this time, stirring is stopped and pH is checked to range from 6 to 6.5. Finally, the resulting gel is de-aerated under mild vacuum. Example 3: Preparation of a gel starting from tromethamine ( + )-( S )-2-( 3-benzoylphenyl )propionate using triethanolamine as neutralizing agent.
A 200 L reactor equipped with a stirrer is loaded with 40.8 L of ethanol, 0.1 kg of a suitable essence oil, 57.5 L of demineralized water and 1.5 kg of carbomer. The mixture is stirred to a homogeneous dispersion (15 min). The resulting dispersion is added with a solution of 1.58 kg of triethanolamine, 1.85 kg of tromethamine (+)-(S)-2-(3-benzoylphenyl)propionate and 5.47 L of water, stirring to obtain a correct incorporation (15 min). After this time, stirring is stopped and pH is checked to range from 6 to 6.5. Finally, the resulting gel is de-aerated under mild vacuum.
Example 4: Preparation of a gel starting from (+)-(S)-2-
(3-benzoylphenyl)propionic acid. A 1500 L reactor equipped with a stirrer is loaded with 408 litres of ethanol and 12.5 kg of ( + )-(S)-2-( 3- benzoylphenyl )propionic acid and 1.0 kg of a suitable essence oil. The mixture is stirred for 15 minutes.
After this time, it is added with a dispersion of carbomer (15 kg) and demineralized water (575 L), prepared mixing the two components and stirring vigorously by a mechanical stirrer. The resulting dispersion is stirred until a correct homogenization (20 min), subsequently it is added with a solution of tromethamine (21 kg) in demineralized water (55.5 L) and stirred to obtain a correct incorporation (15 min). After this time, stirring is stopped and pH is checked to range from 6 to 6.5. Finally, the resulting gel is de-aerated under mild vacuum.

Claims

1. A process for the preparation of a semisolid pharmaceutical formulation containing ( + )-( S)-2-( 3- benzoylphenyl)propionic acid tromethamine salt (dexketoprofen trometamol) as therapeutical agent, a gelifying agent and a pharmacologically acceptable amine as neutralizing agent, which process comprises the addition of a solution of the neutralizing amine and of dexketoprofen tromethamol to a dispersion of the gelifying agent in a suitable solvent.
2. A process according to claim 1, wherein the gelifying agent is a carboxyvinyl polymer.
3. A process according to claim 1, wherein the neutralizing agent is selected from diethanolamine, triethanolamine and tromethamine.
4. A process according to claim 3, wherein the neutralizing agent is tromethamine.
5. A process according to any one of claims 1-4, wherein the pH is adjusted ranging from 5 to 7.
6. A process according to claim 5, wherein the pH is adjusted ranging from 6 to 6.5.
7. A process according to any one of claims 1-4, wherein the semisolid formulations is a gel or cream.
8. A semisolid pharmaceutical formulation of dexketoprofen tromethamol comprising a gelifying agent and a neutralizing agent selected from diethanolamine, triethanolamine and tromethamine.
9. A semisolid pharmaceutical formulation according to claim 8 wherein the neutralizing agent is tromethamine.
10. A semisolid pharmaceutical formulation according to claim 8 wherein the gelifying agent is a carboxyvinyl polymer .
PCT/EP1998/003333 1997-06-04 1998-06-04 Semisolid pharmaceutical formulation containing dexketoprofen trometamol WO1998055113A1 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
UA99116289A UA57075C2 (en) 1997-06-04 1998-04-06 Semisolid pharmaceutical formulation containing dexketoprofen trometamol
NZ501487A NZ501487A (en) 1997-06-04 1998-06-04 Semisolid pharmaceutical formulation containing dexketoprofen trometamol
JP50151599A JP2002502407A (en) 1997-06-04 1998-06-04 Semi-solid drug formulation containing dexketoprofentromethamol
EP98937444A EP0996437B1 (en) 1997-06-04 1998-06-04 Semisolid pharmaceutical formulation containing dexketoprofen trometamol
DE69800804T DE69800804T2 (en) 1997-06-04 1998-06-04 SEMI-SOLID PHARMACEUTICAL PREPARATIONS CONTAINING DEXKETOPROFEN-TROMETAMOL
BRPI9810072-6A BR9810072B1 (en) 1997-06-04 1998-06-04 semi-solid pharmaceutical formulation containing dexketoprofen trometamol and process for preparing it.
KR1019997011315A KR100543558B1 (en) 1997-06-04 1998-06-04 Semisolid pharmaceutical formulation containing dexketoprofen trometamol
CA002293589A CA2293589C (en) 1997-06-04 1998-06-04 Semisolid pharmaceutical formulation containing dexketoprofen trometamol
AT98937444T ATE201137T1 (en) 1997-06-04 1998-06-04 SEMI-SOLID PHARMACEUTICAL PREPARATIONS CONTAINING DEXKETOPROFEN-TROMETAMOLE
PL337156A PL190779B1 (en) 1997-06-04 1998-06-04 Method for manufacture of semi-solid pharmaceutical compound containing, as therapeutic agent, the (+)-(s)-2-(3-benzoylphenyl) propionic acid salt with thrometamine and semi-solid pharmaceutical compound containing thrometamol dexketoprophene
EA199900998A EA002026B1 (en) 1997-06-04 1998-06-04 Semisolid pharmaceutical formulation containing dexketoprofen trometamol
AU86244/98A AU728442B2 (en) 1997-06-04 1998-06-04 Semisolid pharmaceutical formulation containing dexketoprofen trometamol
EEP199900556A EE03905B1 (en) 1997-06-04 1998-06-04 Semi-solid pharmaceutical preparations containing dexketoprofen trometamol
SK1649-99A SK284317B6 (en) 1997-06-04 1998-06-04 Semisolid pharmaceutical formulation containing dexketoprofen trometamol
HU0002734A HU226686B1 (en) 1997-06-04 1998-06-04 Semisolid pharmaceutical formulation containing dexketoprofen trometamol
DK98937444T DK0996437T3 (en) 1997-06-04 1998-06-04 Semifast pharmaceutical formulation containing dexketoprofentrometamol
BG103926A BG64299B1 (en) 1997-06-04 1999-11-25 Semisolid pharmaceutical form containing dexketoprophene trometamol
HK00106945A HK1027753A1 (en) 1997-06-04 2000-11-01 Semisolid pharmaceutical formulation containing dexketoprofen trometamol
GR20010401170T GR3036319T3 (en) 1997-06-04 2001-08-03 Semisolid pharmaceutical formulation containing dexketoprofen trometamol

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES009701213A ES2124196B1 (en) 1997-06-04 1997-06-04 PROCEDURE FOR THE MANUFACTURE OF A SEMI-SOLID PHARMACEUTICAL FORM CONTAINING DEXKETOPROPHEN TROMETAMOL AND ITS USE IN THE TOPICAL TREATMENT OF INFLAMMATION.
ESP9701213 1997-06-04

Publications (1)

Publication Number Publication Date
WO1998055113A1 true WO1998055113A1 (en) 1998-12-10

Family

ID=8299560

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/003333 WO1998055113A1 (en) 1997-06-04 1998-06-04 Semisolid pharmaceutical formulation containing dexketoprofen trometamol

Country Status (29)

Country Link
EP (1) EP0996437B1 (en)
JP (1) JP2002502407A (en)
KR (1) KR100543558B1 (en)
CN (1) CN1195510C (en)
AT (1) ATE201137T1 (en)
AU (1) AU728442B2 (en)
BG (1) BG64299B1 (en)
BR (1) BR9810072B1 (en)
CA (1) CA2293589C (en)
CU (1) CU22866A3 (en)
CZ (1) CZ290118B6 (en)
DE (1) DE69800804T2 (en)
DK (1) DK0996437T3 (en)
EA (1) EA002026B1 (en)
EC (1) ECSP014108A (en)
EE (1) EE03905B1 (en)
ES (2) ES2124196B1 (en)
GR (1) GR3036319T3 (en)
HK (1) HK1027753A1 (en)
HN (1) HN2001000137A (en)
HU (1) HU226686B1 (en)
ID (1) ID26240A (en)
NZ (1) NZ501487A (en)
PL (1) PL190779B1 (en)
PT (1) PT996437E (en)
SK (1) SK284317B6 (en)
TR (1) TR199903018T2 (en)
UA (1) UA57075C2 (en)
WO (1) WO1998055113A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19935159A1 (en) * 1999-07-27 2001-02-22 Schuster Wolfgang Muscle relaxant lotion containing natural active agents and penetration enhancing carrier
FR2797766A1 (en) * 1999-08-27 2001-03-02 Menarini France Paste in gel form for topical application, containing an anti-inflammatory, an antibiotic or a phlebotonic
WO2013022410A2 (en) 2011-08-08 2013-02-14 Mahmut Bilgic Production method for effervescent formulations comprising dexketoprofen
EP2764875A1 (en) * 2013-02-06 2014-08-13 Galenicum Health S.L. Process for preparing a stable pharmaceutical composition comprising dexketoprofen trometamol
WO2016016353A1 (en) * 2014-07-30 2016-02-04 Pierre Fabre Medicament Stearate emulsions

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2667465C2 (en) * 2015-10-28 2018-09-19 Закрытое Акционерное Общество "Фармфирма "Сотекс" Pharmaceutical composition for external use containing a salt of dexketoprofen, and a process for its preparation
CN109303762A (en) * 2017-07-28 2019-02-05 韩美药品株式会社 Semisolid preparation and preparation method thereof containing Ketoprofen
KR101935830B1 (en) * 2018-02-13 2019-01-07 주식회사 오스테오시스 External counterpulsation system and control method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE886486A (en) * 1979-12-05 1981-04-01 Menarini Sas PHARMACEUTICAL FORM "GEL" CONTAINING 2- (3-BENZOYL-PHENYL) -PROPIONIC ACID AND ITS USE IN THERAPEUTICS FOR LOCAL USE
US5091182A (en) * 1990-07-23 1992-02-25 Syntex (U.S.A.) Inc. Dispensing units for ketorolac topical gel formlations
WO1994011332A1 (en) * 1992-11-10 1994-05-26 Laboratorios Menarini S.A. A novel arylpropionic derivative, a process for the preparation and the use thereof as an analgesic agent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2319340A1 (en) * 1975-07-28 1977-02-25 Roussel Uclaf NEW SALT OF A-METHYL BENZOYL-5-THIOPHENE-2 ACETIC ACID, METHOD OF PREPARATION AND APPLICATION AS A MEDICINAL PRODUCT
IT1207994B (en) * 1986-01-03 1989-06-01 Therapicon Srl WATER SOLUBLE SALTS OF ANTI-INFLAMMATORY AND ANALGESIC ADAPTITY COMPOUNDS, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS.
US4960892A (en) * 1988-06-10 1990-10-02 American Home Products Corporation Naphthalenepropionic acid derivatives as anti-inflammatory/anti-allergic agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE886486A (en) * 1979-12-05 1981-04-01 Menarini Sas PHARMACEUTICAL FORM "GEL" CONTAINING 2- (3-BENZOYL-PHENYL) -PROPIONIC ACID AND ITS USE IN THERAPEUTICS FOR LOCAL USE
US5091182A (en) * 1990-07-23 1992-02-25 Syntex (U.S.A.) Inc. Dispensing units for ketorolac topical gel formlations
WO1994011332A1 (en) * 1992-11-10 1994-05-26 Laboratorios Menarini S.A. A novel arylpropionic derivative, a process for the preparation and the use thereof as an analgesic agent

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19935159A1 (en) * 1999-07-27 2001-02-22 Schuster Wolfgang Muscle relaxant lotion containing natural active agents and penetration enhancing carrier
FR2797766A1 (en) * 1999-08-27 2001-03-02 Menarini France Paste in gel form for topical application, containing an anti-inflammatory, an antibiotic or a phlebotonic
WO2013022410A2 (en) 2011-08-08 2013-02-14 Mahmut Bilgic Production method for effervescent formulations comprising dexketoprofen
EP2764875A1 (en) * 2013-02-06 2014-08-13 Galenicum Health S.L. Process for preparing a stable pharmaceutical composition comprising dexketoprofen trometamol
WO2016016353A1 (en) * 2014-07-30 2016-02-04 Pierre Fabre Medicament Stearate emulsions
FR3024360A1 (en) * 2014-07-30 2016-02-05 Pf Medicament EMULSIONS TO STEARATES

Also Published As

Publication number Publication date
ES2124196B1 (en) 1999-12-01
SK164999A3 (en) 2000-09-12
CZ290118B6 (en) 2002-06-12
ES2124196A1 (en) 1999-01-16
AU728442B2 (en) 2001-01-11
HN2001000137A (en) 2001-10-29
KR100543558B1 (en) 2006-01-20
HUP0002734A2 (en) 2001-01-29
ATE201137T1 (en) 2001-06-15
PL337156A1 (en) 2000-07-31
BG103926A (en) 2000-09-29
JP2002502407A (en) 2002-01-22
DE69800804T2 (en) 2001-09-13
ECSP014108A (en) 2002-02-25
DK0996437T3 (en) 2001-08-06
BR9810072A (en) 2000-09-19
CN1195510C (en) 2005-04-06
GR3036319T3 (en) 2001-11-30
CN1259048A (en) 2000-07-05
EP0996437A1 (en) 2000-05-03
BR9810072B1 (en) 2010-07-13
HK1027753A1 (en) 2001-01-23
CZ431399A3 (en) 2000-05-17
EA002026B1 (en) 2001-12-24
PL190779B1 (en) 2006-01-31
EP0996437B1 (en) 2001-05-16
PT996437E (en) 2001-09-28
DE69800804D1 (en) 2001-06-21
ES2156446T3 (en) 2001-06-16
EE9900556A (en) 2000-06-15
EA199900998A1 (en) 2000-06-26
CU22866A3 (en) 2003-08-13
CA2293589C (en) 2008-01-22
HUP0002734A3 (en) 2003-05-28
KR20010013320A (en) 2001-02-26
SK284317B6 (en) 2005-01-03
CA2293589A1 (en) 1998-12-10
HU226686B1 (en) 2009-06-29
EE03905B1 (en) 2002-12-16
UA57075C2 (en) 2003-06-16
TR199903018T2 (en) 2000-05-22
AU8624498A (en) 1998-12-21
NZ501487A (en) 2001-06-29
ID26240A (en) 2000-12-07
BG64299B1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
EP0101178B1 (en) Topical anti-inflammatory compositions
CY1108488T1 (en) Solid Compositions Containing Gamma-Aminobutyric Acid Derivatives and Method for Their Preparation
CH630260A5 (en) ANTIBIOTIC COMPOSITIONS BASED ON A TETRACYCLINE.
KR20160091424A (en) Compositions for continuous administration of DOPA decarboxylase inhibitors
JPH078786B2 (en) Percutaneously absorbable hydrous preparation of arylpropionic acid derivative and method for producing the same
JP2008542260A (en) Novel injectable composition and method for its preparation
EP0996437B1 (en) Semisolid pharmaceutical formulation containing dexketoprofen trometamol
EP3097907B1 (en) A gel formulation comprising analgesic and anesthesic agents
US4621075A (en) Gel-form topical antibiotic compositions
US4602040A (en) Meclofenamic acid topical pharmaceutical composition
JP3608209B2 (en) Crotamiton combination external preparation
EP2292218B1 (en) Topical application of nimesulide and thiocolchicoside
MXPA99011180A (en) Semisolid pharmaceutical formulation containing dexketoprofen trometamol
JPH08259464A (en) Local anesthetic composition
EP2340016B1 (en) Topical formulation of 3-(2,2,2-trimethylhydrazinium) propionate dihydrate
GB2327041A (en) Topical Analgesic Composition
EP0492747B1 (en) Pharmaceutical preparation for topical application
JPS63287721A (en) Anti-inflammatory analgesic gel agent
JP3313894B2 (en) Transdermal absorption enhancer and skin external preparation
GB2236250A (en) Ibuprofen solutions and topical compositions
JPH05117141A (en) Antiinflammatory analgesic gel preparation containing adrenal essence
JP3522832B2 (en) Percutaneous absorption enhancer and external preparation for skin
IL100595A (en) Pharmaceutical preparation for topical application comprising a clonixinate salt

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98805741.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998937444

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2293589

Country of ref document: CA

Ref document number: 2293589

Country of ref document: CA

Kind code of ref document: A

Ref document number: 1999 501515

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 164999

Country of ref document: SK

Ref document number: PA/a/1999/011180

Country of ref document: MX

Ref document number: PV1999-4313

Country of ref document: CZ

Ref document number: 86244/98

Country of ref document: AU

Ref document number: 09445095

Country of ref document: US

Ref document number: 1019997011315

Country of ref document: KR

Ref document number: 501487

Country of ref document: NZ

Ref document number: 1999/03018

Country of ref document: TR

Ref document number: 199900998

Country of ref document: EA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998937444

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1999-4313

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019997011315

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 86244/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1998937444

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: PV1999-4313

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1019997011315

Country of ref document: KR